Shouldn't adults with growth hormone deficiency be offered growth hormone replacement therapy?

Annals of Internal Medicine

Volumn 137, Issue 3, 2002, Pages 197-201

  Cook, David M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HYPOPITUITARISM; LABORATORY DIAGNOSIS; MALIGNANT NEOPLASTIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; REVIEW;

EID: 0037031239     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-3-200208060-00012     Document Type: Review

References (47)

1. Premature mortality due to cardiovascular disease in hypopituitarism
2. The effect of hypopituitarism on life expectancy
3. Increased cerebrovascular mortality in patients with hypopituitarism
4. Increased mortality in hypopituitarism is not due to an increase in vascular mortality
5. Premature mortality in 1014 patients with hypopituitarism
6. Growth hormone replacement therapy is not associated with any increase in mortality
7. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency
8. Reduced bone mineral density in patients with adult onset growth hormone deficiency
9. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism
10. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency
11. Bisphosphonates: From the laboratory to the clinic and back again
12. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency
13. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender
14. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH
15. Whole body and regional soft tissue changes in growth hormone deficient adults after one year of growth hormone treatment: A double-blind, randomized, placebo-controlled study
16. Discontinuation of growth hormone (GH) treatment: Metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects
17. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency
18. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations
19. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients
20. The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance
21. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults
22. Increased arterial intima-media thickness in childhood-onset growth hormone deficiency
23. Growth hormone (GH) treatment reverses early atheroscletotic changes in GH-deficient adults
24. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients
25. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review
26. Alterations of monocyte function in patients with growth hormone (GH) deficiency: Effect of substitutive GH therapy
27. Effects of growth hormone administration on inflammatory and other cardiovascular risk markets in men with growth hormone deficiency. A randomized, controlled clinical trial
28. Lymphocyte subsets and natural-killer activity in growth hormone deficiency
29. A newly defined property of somatottopin: Priming of mactophages for production of superoxide anion
30. The pituitary gland is required for protection against lethal effects of Salmonella typhimurium
31. Quality of life in adults with growth hormone (GH) deficiency: Response to treatment with tecombinant human GH in a placebo-controlled 21-month trial
32. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters
33. Two years of replacement therapy in adults with growth hormone deficiency
34. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults
35. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood
36. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency
37. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?
38. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism
39. Increased mortality associated with growth hormone treatment in critically ill adults
40. Prospective study of colotectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
41. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
42. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
43. Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan
44. Mortality and cancer incidence in acromegaly: A retrospective cohort study
45. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults
46. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults
47. Factors influencing the desire for long-term growth hormone replacement in adults